Real World Patient-reported Outcomes in HIV-infected Adults Switching to EVIPLERA®, Because of a Previous Intolerance to cART. PRO-STR Study.

Journal: Current HIV research
PMID: 30760189

Abstract

BACKGROUND: To investigate the impact of switching from stable Combined Antiretroviral Therapy (cART) to single-tablet regimen (RPV/FTC/TDF=EVIPLERA® /COMPLERA®) on patient- reported outcomes in HIV-infected adults who cannot tolerate previous cART, in a real-world setting.

Authors

  • D Podzamczer
    Hospital Universitari de Bellvitge, Barcelona, Spain.
  • N Rozas
    Hospital Universitari de Bellvitge, Barcelona, Spain.
  • P Domingo
    Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
  • C Miralles
    Hospital Xeral de Vigo, Pontevedra, Spain.
  • E Van den Eynde
    Hospital Universitari de Bellvitge, Barcelona, Spain.
  • A Romero
    Hospital de Especialidades de Puerto Real, Cadiz, Spain.
  • E Deig
    Hospital General de Granollers, Barcelona, Spain.
  • H Knobel
    Hospital del Mar, Barcelona, Spain.
  • J Pasquau
    Hospital Universitario Virgen de las Nieves, Granada, Spain.
  • A Antela
    Complejo Hospitalario Universitario de Santiago, A Coruna, Spain.
  • B Clotet
    Hospital Universitari Germans Trias i Pujol, Barcelona, Spain.
  • P Geijo
    Hospital Virgen de la Luz, Cuenca, Spain.
  • E Rodríguez de Castro
    Hospital Mateu Orfila, Mahon, Spain.
  • M A Casado
    Pharmacoeconomics & Outcomes Research Iberia, Madrid, Spain.
  • A Muñoz
    Pharmacoeconomics & Outcomes Research Iberia, Madrid, Spain.
  • A Casado
    Pharmacoeconomics & Outcomes Research Iberia, Madrid, Spain.
  • For The Pro-Str Study Group

Keywords

External Resources

Popular Topics
Recent Journals